Worldwide, lung cancer is the most common cause of cancer-related deaths. Molecular
targeted therapies and immunotherapies for non-small-cell lung cancer (NSCLC) have …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

Cancer is one of the main causes of death worldwide. To date, and despite the advances in
conventional treatment options, therapy in cancer is still far from optimal due to the non …

Despite the improvement in clinical outcomes derived by the introduction of epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful …